Search

Your search keyword '"Esteve, Jordi"' showing total 1,062 results

Search Constraints

Start Over You searched for: Author "Esteve, Jordi" Remove constraint Author: "Esteve, Jordi" Publication Year Range Last 10 years Remove constraint Publication Year Range: Last 10 years
1,062 results on '"Esteve, Jordi"'

Search Results

1. Allogeneic stem cell transplantation in de novo core-binding factor acute myeloid leukemia in first complete remission: data from the EBMT

2. Clinical management of patients diagnosed with acute myeloid leukemia treated with venetoclax in combination with hypomethylating agents after achieving a response: a real-life study

3. Allogeneic hematopoietic cell transplantation with sequential conditioning regimen in relapsed refractory acute myeloid leukemia

4. EASIX and cardiac adverse events after allogeneic hematopoietic cell transplantation

9. Survival improvement of patients with FLT3 mutated acute myeloid leukemia: results from a prospective 9 years cohort

10. Venetoclax–based low intensity therapy in molecular failure of NPM1-mutated AML

11. AML typical mutations (CEBPA, FLT3, NPM1) identify a high-risk chronic myelomonocytic leukemia independent of CPSS molecular

12. Endothelial Activation and Stress Index in adults undergoing allogeneic hematopoietic cell transplantation with post-transplant cyclophosphamide-based prophylaxis

13. Germ line variants in patients with acute myeloid leukemia without a suspicion of hereditary hematologic malignancy syndrome

14. Hyponatremia induced by post-transplant cyclophosphamide in allogeneic hematopoietic cell transplantation

15. Incidence, risk factors, and impact of early cardiac toxicity after allogeneic hematopoietic cell transplant

16. Clinical applications of donor lymphocyte infusion from an HLA-haploidentical donor: consensus recommendations from the Acute Leukemia Working Party of the EBMT

17. Measurable residual disease (MRD) status before allogeneic hematopoietic cell transplantation impact on secondary acute myeloid leukemia outcome. A Study from the Acute Leukemia Working Party (ALWP) of the European society for Blood and Marrow Transplantation (EBMT)

18. Long-term outcomes in patients with relapsed/refractory acute myeloid leukemia and other high-risk myeloid malignancies after undergoing sequential conditioning regimen based on IDA-FLAG and high-dose melphalan

19. Applicability and validation of different prognostic scores in allogeneic hematopoietic cell transplant (HCT) in the post-transplant cyclophosphamide era

20. Phase 3 trial of gilteritinib plus azacitidine vs azacitidine for newly diagnosed FLT3mut+ AML ineligible for intensive chemotherapy

21. Ponatinib, chemotherapy, and transplant in adults with Philadelphia chromosome–positive acute lymphoblastic leukemia

22. Long-term results and GvHD after prophylactic and preemptive donor lymphocyte infusion after allogeneic stem cell transplantation for acute leukemia

24. European LeukemiaNet 2017 risk stratification for acute myeloid leukemia: validation in a risk-adapted protocol

26. Efficacy of escalating therapy with brentuximab vedotin‐AVD in advanced stage Hodgkin lymphoma patients with positive interim positron emission tomography after ABVD.

27. Whole Exome Sequencing of Intermediate-Risk Acute Myeloid Leukemia without Recurrent Genetic Abnormalities Offers Deeper Insights into New Diagnostic Classifications.

28. Regulating i-Voting Within Countries and Parties

29. Prognostic Factors in AML

30. Post-Transplantation Cyclophosphamide and Tacrolimus for Graft-versus-Host Disease Prevention after Allogeneic Hematopoietic Cell Transplantation from HLA-Matched Donors Has More Advantages Than Limitations

31. Isocitrate Dehydrogenase (IDH) 1 and 2 Mutations Predicts Better Outcome in Patients with Acute Myeloid Leukemia Undergoing Allogeneic Hematopoietic Cell Transplantation: a study of the ALWP of the EBMT

32. Ponalfil trial for adults with Philadelphia chromosome‐positive acute lymphoblastic leukemia: Long‐term results

33. Continuously improving outcome over time after second allogeneic stem cell transplantation in relapsed acute myeloid leukemia - an EBMT registry analysis of 1540 patients

34. Real‐Life Comparison of Antivirals for SARS‐CoV‐2 Omicron Infection in Patients With Hematologic Malignancies

35. Infrequent Presentations of Chronic NPM1-Mutated Myeloid Neoplasms: Clinicopathological Features of Eight Cases from a Single Institution and Review of the Literature

36. Allogeneic Stem Cell Transplantation for Patients with Acute Myeloid Leukemia with Myelodysplasia-Related Features in First Complete Remission As per the International Consensus Classification (ICC) 2022: A Study from the ALWP of the EBMT

37. Allogeneic hematopoietic stem cell transplantation for adult patients with t(4;11)(q21;q23) KMT2A/AFF1 B-cell precursor acute lymphoblastic leukemia in first complete remission: impact of pretransplant measurable residual disease (MRD) status. An analysis from the Acute Leukemia Working Party of the EBMT

39. Clinical Characteristics and Outcome of Bloodstream Infections in HIV-Infected Patients with Cancer and Febrile Neutropenia: A Case–Control Study

40. Allogeneic HCT for adults with B-cell precursor acute lymphoblastic leukemia harboring IKZF1 gene mutations. A study by the Acute Leukemia Working Party of the EBMT

41. Management of patients with acute leukemia during the COVID-19 outbreak: practical guidelines from the acute leukemia working party of the European Society for Blood and Marrow Transplantation

43. Evaluation of European LeukemiaNet 2022 risk classification in patients undergoing allogeneic haematopoietic stem cell transplantation for acute myeloid leukaemia: Identification of a very poor prognosis genetic group.

44. Continuously improving outcome over time after second allogeneic stem cell transplantation in relapsed acute myeloid leukemia: an EBMT registry analysis of 1540 patients.

45. Next Generation Sequencing Study of clonal Evolution in AML Shows Mutations in RAS-MAPK Signaling Pathway as an Emergent Mechanism of Progression in Low-Intensity Treatments

46. Complex karyotype but not other cytogenetic abnormalities is associated with worse posttransplant survival of patients with nucleophosmin 1‐mutated acute myeloid leukemia: A study from the European Society for Blood and Marrow Transplantation Acute Leukemia Working Party

47. Measurable residual disease (MRD) testing for acute leukemia in EBMT transplant centers: a survey on behalf of the ALWP of the EBMT

48. Allogeneic hematopoietic cell transplantation for acute myeloid leukemia with hyperdiploid complex karyotype

49. KB-Lanra 1001: A Phase 1b/2 Study of Safety, PK, PD, and Preliminary Efficacy of the Selective SYK Inhibitor Lanraplenib in Combination with the FLT3 Inhibitor Gilteritinib in FLT3-Mutated R/R AML

50. Characteristics and long‐term outcome in a large series of chronic myelomonocytic leukaemia patients including 104 formerly referred to as oligomonocytic

Catalog

Books, media, physical & digital resources